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Abstract
Background: Two meta-analyses of genome-wide association studies (GWAS) have suggested that four variants: rs2605100
in lysophospholipase-like 1 (LYPLAL1), rs10146997 in neuroxin 3 (NRXN3), rs545854 in methionine sulfoxide reductase A
(MSRA), and rs987237 in transcription factor activating enhancer-binding protein 2 beta (TFAP2B) associate with measures of
central obesity.To elucidate potential underlying phenotypes we aimed to investigate whether these variants associated
with: 1) quantitative metabolic traits, 2) anthropometric measures (waist circumference (WC), waist-hip ratio, and BMI), or 3)
type 2 diabetes, and central and general overweight and obesity.
Methodology/Principal Findings: The four variants were genotyped in Danish individuals using KASParH. Quantitative
metabolic traits were examined in a population-based sample (n=6,038) and WC and BMI were furthermore analyzed in a
combined study sample (n=13,507). Case-control studies of diabetes and adiposity included 15,326 individuals. The major
G-allele of LYPLAL1 rs2605100 associated with increased fasting serum triglyceride concentrations (per allele effect
(b)=3%(1;5(95%CI)), padditive=2.7610
23), an association driven by the male gender (pinteraction=0.02). The same allele
associated with increased fasting serum insulin concentrations (b=3%(1;5), padditive=2.5610
23) and increased insulin
resistance (HOMA-IR) (b=4%(1;6), padditive=1.5610
23). The minor G-allele of rs10146997 in NRXN3 associated with increased
WC among women (b=0.55cm (0.20;0.89), padditive=1.7610
23, pinteraction=1.0610
23), but showed no associations with
obesity related metabolic traits. The MSRA rs545854 and TFAP2B rs987237 showed nominal associations with central obesity;
however, no underlying metabolic phenotypes became obvious, when investigating quantitative metabolic traits. None of
the variants influenced the prevalence of type 2 diabetes.
Conclusion/Significance: We demonstrate that several of the central obesity-associated variants in LYPLAL1, NRXN3, MSRA,
and TFAP2B associate with metabolic and anthropometric traits in Danish adults. However, analyses were made without
adjusting for multiple testing, and further studies are needed to confirm the putative role of LYPLAL1, NRXN3, MSRA, and
TFAP2B in the pathophysiology of obesity.
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Introduction
Obesity is a major health problem with increasing prevalence in
Western societies, and obesity, as well as the often associated insulin
resistance (IR), are important risk factors for type 2 diabetes,
cardiovascular diseases, hypertension, and several other chronic
diseases.Toprovide new insightintothepathophysiologyofobesity,
genome-wide association studies (GWAS) have in the last few years
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20640been performed with elaborating results [1,2,3,4,5,6,7] identifying
variants associated with body mass index (BMI) – an indirect
measure of general adiposity. Following, two meta-analyses
demonstrated four loci to associate with measures of central
adiposity (waist circumference (WC) and waist–hip-ratio (WHR)):
1) a meta-analysis of 16 GWAS (n=38,580) with follow-up studies
in a maximum of 118,691 individuals of European origin, identified
variants near lysophospholipase-like 1 (LYPLAL1), methionine
sulfoxide reductase A (MSRA), and transcription factor activating
enhancer-binding protein 2 beta (TFAP2B), to strongly associate
with measures of central adiposity using information about adult
WC and WHR [8], and 2) a large-scale meta-analysis of GWAS
from the CHARGE Consortium involving 70,014 Caucasian
individuals identified neuroxin 3 (NRXN3) as a novel locus for
central adiposity [9].
Lysophospholipase-like 1 protein, encoded by LYPLAL1, is
thought to act as a triglyceride lipase and reported to be up-
regulated in subcutaneous adipose tissue of obese individuals [10].
In the meta-analysis of 16 GWAS, the major G-allele of rs2605100
in LYPLAL1 associated with increased WHR (p=2.6610
28) only
among women [8]. NRXN3 encodes the neuroxines protein family
that functions in the vertebrate nervous system as cell adhesion
molecules and receptors. In patients with schizophrenia, NRXN3
has been demonstrated to associate with alcohol dependence and
the degree of nicotine dependence [11,12]. The minor G-allele of
rs10146997 in NRXN3 associated with WC (p=6.4610
27) and
BMI (p=7.4610
26) in the CHARGE GWAS; however, the
association with WC attenuated (p=0.32), when adjusted for BMI
[9]. MSRA encodes an antioxidant enzyme that repairs proteins
inactivated by oxidative damage, but the biological connections
between the MSRA locus and adiposity are unclear [8]. In the
meta-analysis of 16 GWAS, a strong association was found with
the minor G-allele of rs545854 in MSRA and central obesity
measured by WC (p=8.9610
29) (mixed-gender analysis) [8]. The
association diminished (p=0.11), when adjusted for BMI.
The binding-protein encoded by TFAP2B is expressed in
adipose tissue [13]. Studies have shown an association between
TFAP2B and type 2 diabetes, and over-expression of TFAP2B in
adipocytes leads to IR and accumulation of triglycerides inside the
adipocytes [13,14,15]. In a study of 1,176 adolescents, Nordquist et
al. found that men carrying the 4 repeat allele of intron 2
polymorphism (intronic variable number tandem repeat) of
TFAP2B had higher insulin sensitivity and central obesity
(measured by skin folds) [16]. Another study, comprising 81
individuals suggested that TFAP2B might be a novel candidate
gene for development of the metabolic syndrome, as it was shown
to regulate the expression of various adipokines [17]. In the meta-
analysis of 16 GWAS, the minor G-allele of rs987237 in TFAP2B
associated significantly with central obesity measured by WC
(p=1.9610
211) and general obesity measured by BMI (p=
7.0610
212 (stage 2 alone)) in the mixed-gender analysis [8].
Although these genes are considered obvious candidates for
obesity, the causal variants and their role in the pathogenesis of
obesity remain to be elucidated.
The aim of the present study was to investigate central obesity-
associated variants in LYPLAL1, NRXN3, MSRA, and TFAP2B for
associations with quantitative metabolic traits in a population-
based sample of 6,038 adult Danes (The Inter99 study sample). In
addition, we examined associations between these variants and
anthropometric measures (WC, WHR, and BMI) in a larger group
of individuals. Also, we conducted large case-control studies
involving a total of 15,326 Danes, investigating associations
between these variants and type 2 diabetes, as well as both central
and general overweight and obesity. Since three of the variants
(LYPLAL1, MSRA, and TFAP2B) in previous studies have been
investigated using sex-stratified analyses, we performed all analyses
stratified according to sex.
Results
In the Inter99 population, the major G-allele of rs2605100 in
LYPLAL1 associated with fasting serum triglyceride concentrations
(per allele effect(b)=3%, ((95% confidence interval(CI))1;5),
padditive (add)=2.7610
23), fasting serum insulin concentrations
(b=3% (1;5), padd=2.5610
23), and homeostasis model assess-
ment-insulin resistance (HOMA-IR) (b=4% (1;6), padd=
1.5610
23) (table 1). When stratifying according to sex the
association with fasting serum triglycerides was restricted to men
(b=6% (3;9), padd=2.4610
24) (table 1). Indeed, the interaction
analysis revealed an interaction between sex and genotype for
triglyceride levels (pint=0.02) (Table S2). Furthermore, we found a
borderline association between rs2605100 and decreased BMI
(b=20.18 kg/m
2 (20.36;21610
23), padd=0.05), and decreased
WC (b=20.08 cm (20.29;0.13), padd=0.04) (table 1). However,
the association with WC diminished, when adjusted for BMI
(padd=0.47) (Table S2). The combined quantitative trait (QT)
analysis showed associations with decreased WC (b=20.48 cm
(20.81;0.16), padd=0.004) and BMI (b=20.16 kg/m
2 (20.28;
20.04), padd=0.01), but the associations diminished, when data
were adjusted for BMI (padd=0.12) and WC (padd=0.87),
respectively (Table S3 and Table S4). In the case-control study
the variant associated with central obesity, measured by WC
(Odds Ratio(OR)add=0.92 (0.86–0.98(95% CI)), padd=0.01)
(table 2), and the association strengthened, when WC was adjusted
for BMI (padd=0.004) (Table S3). No other significant associations
were found for central or general obesity (table 2).
The minor G-allele rs10146997 of NRXN3 associated with
increased WC among women (b=0.55 cm (0.20;0.89), padd=
1.7610
23) (table 2) in the Inter99, which was underpinned by the
interaction analysis (pint=1.0610
23) (Table S5). The significance
level attenuated, when adjusted for sex and age only (Table S5).
This association was not found in the larger combined QT analysis
(TableS3).Neitherwereweabletoshowanyassociationswithother
obesity-related metabolic phenotypes. In the case-control analyses
the variant showed no association with general adiposity, measured
by BMI (ORadd=1.02 (0.94–1.11), padd=0.66) (Table S4). No
interaction between sex and genotype was found in these analyses.
The rs545854 minor G-allele in MSRA associated with decreased
fasting serum insulin concentrations (b=24% (28;21), padd=
0.02), and HOMA-IR (b=25% (29;21), padd=0.02) among men
(table 1). However, the interaction analysis did not show any
interaction between sex and genotype for the two traits (pint=0.08)
(Table S6). The variant was not associated with other quantitative
metabolic or anthropometric traits (Table S3, S4, and S6). When
comparing the genotype distribution between lean and obese
individuals a borderline association between rs545854 and central
obesity was observed (ORadd=1.08 (1.00–1.18), padd=0.05)
(table 2), and when adjusted for BMI, this association was streng-
thened (padd=0.02) (Table S3).
The minor G-allele rs987237 in TFAP2B did not associate with
any metabolic traits in the QT analysis (Table S3, S4, and S7).
However, the variant was borderline associated with central
obesity (ORadd=1.08 (1.0–1.17), padd=0.06) in the case-control
analysis (Table S3). This borderline association became nominal
significant, when stratified to women (ORadd=1.17 (1.03–1.32),
padd=0.01; pint=0.04). When adjusted for BMI, the association
became stronger among women (padd=0.001) and it also became
evident among men (padd=0.01) (Table S3).
Obesity-Related Variants and Metabolic Traits
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the investigated variants, except for TFAP2B rs987237 in the
combined QT analysis in relation to general obesity (BMI) (Fixed
effect, I
2: 78%[41%–92%], p=0.003) (Table S4).
None of the variants associated with central and general over-
weight, or type 2 diabetes in the case-control analyses (data not
shown).
Discussion
In this study we found several associations with quantitative
metabolic and anthropometric traits for the central obesity-
associated variants in LYPLAL1, NRXN3, MSRA, and TFAP2B.
As a major finding the G-allele (risk-allele) of rs2605100 in
LYPLAL1 associated with elevated concentrations of fasting serum
triglycerides and fasting serum insulin and with estimates of central
obesity. In a recent meta-analysis of 32 GWAS for WHR, a
variant in LYPLAL1 (rs4846567) in high linkage disequilibrium
(r
2=0.64, D’=0.84, HapMap CEU population) with rs2605100
achieved genome-wide significance, and the subsequent associa-
tion analyses with related metabolic traits in 77,167 participants
(follow-up comprising up to 113,636 subjects) showed that this
variant associated with increased levels of serum triglycerides
(p=0.018), fasting insulin (p=1.1610
25), and HOMA-IR (p=
9.8610
26) [18]. These previously reported findings strengthen the
present observations in our somewhat smaller study population.
Moreover, we additionally investigated sex-specific effects of
rs2605100 and found that the association with fasting serum
triglycerides was restricted to men. This association has not
previously been reported.
Our findings for rs2605100 in LYPLAL1 are in line with
previous observations that a higher fat-mass causes increased
lipogenesis, resulting in higher levels of circulating triglycerides
and IR [19,20,21]. In mice, it has been demonstrated that insulin
inhibits the breakdown of fat in adipose tissue by inhibiting
the intracellular triglyceride lipase in the beta-cell [10,21]. The
elevated triglyceride concentrations may result from an increased
expression of the lipase gene, which then facilitates higher
triglyceride lipase activity in the adipose tissue. Furthermore,
obesity is associated with an increased number and/or size of
adipose cells. These cells respond more poorly to insulin, as they
have impaired insulin signaling, resulting in increased activity of
the lipoprotein lipases, including the triglyceride lipase. The
increased lipase activity and increased mass of adipose tissue lead
Table 1. Variants showing statistical significant associations with quantitative metabolic traits (n=6,038).
Quantitative metabolic traits
Variant BMI (kg/m2) WC (cm) WHR
Fasting serum
triglyceride
Fasting serum
insulin
Fasting plasma
glucose
Insulin resistance,
HOMA-IR
LYPLAL1 rs2605100
All 20.18 (20.36;
21610
23),
0.05
20.08 (20.29;
0.13),
0.04
3% (1;5),
2.7610
23
3% (1;5),
2.5610
23
4% (1;6),
1.5610
23
Men 6% (3;9),
2.4610
24
Women 4% (1;6),
0.01
1% (0;1),
0.04
4% (1;7),
6.0610
23
NRXN3 rs10146997
Women 0.55 (0.20;
0.89),
0.02
4610
23 (26
10
24;0.01),
0.02
MSRA rs545854
Men 24% (28;21),
0.02
25% (29;21),
0.02
The table includes effect sizes and p-values (b (95% CI), p-value) for significant associations only.
Values of fasting serum triglycerides, serum insulin, plasma glucose, and HOMA-IR were logarithmically transformed prior to statistical analyses, and their effect sizes (b)
are presented as the increase/decrease in percent. P-values were calculated assuming an additive model (padd). BMI, waist circumference and waist-hip ratio were
adjusted for age and sex.
doi:10.1371/journal.pone.0020640.t001
Table 2. Variants showing statistical significant associations
with BMI and/or WC in the case-control analyses (n=15,326).
BMI WC
OR (95%CI), p-value OR (95%CI), p-value
LYPLAL1 rs2605100
All 0.92(0.86–0.98), 0.004
Men 0.89(0.82–0.97), 0.0004
NRXN3 rs10146997
All 1.02 (0.94–1.11), 0.04
Women 1.04 (0.93–1.17), 0.04
MSRA rs545854
All 1.08(1.00–1.18), 0.02
Women 1.09(0.96–1.23), 0.04
TFAP2B rs987237
Men 1.01 (0.91–1.13), 0.01
Women 1.17 (1.03–1.32), 0.001
The effect is the odds ratio (OR) presented as the increase/decrease and 95%
confidence interval (CI). Effect and p-values shown are for an additive genetic
model (padd) and are adjusted for age, sex, and diabetes treatment for the
obese cases. BMI, body mass index; WC, waist circumference.
doi:10.1371/journal.pone.0020640.t002
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the development of IR [22]. Thus, this underlying insulin resistant
phenotype might add to explain the associations found between
the LYPLAL1 variant and obesity.
The minor G-allele rs10146997 in NRXN3 associated with
increased WC among women, but we found no clear association
with BMI as reported in a recent meta-analysis of 249,796
individuals [23]. Neither did we observe an association between
rs10146997 and fasting serum insulin levels nor IR (HOMA-IR) as
reported for rs10150332 in NRXN3 (r
2=1.00, D’=1.00, HapMap
CEU population) in the meta-analysis [23]. The reason for these
inconsistencies may be 1) lack of statistical power in our study due
to the relatively low minor allele frequency, or 2) the association
observed in the meta-analysis may reflect a random correlation
between IR and BMI.
In this study, the MSRA rs545854 minor G-allele showed
associations with decreased fasting levels of serum insulin and
decreased HOMA-IR among men, but no association with obesity
was evident. The latter finding is consistent with the recent meta-
analyses that failed to demonstrate genome-wide significant
evidence of associations between this variant and BMI or WHR
[18,23]. Also, analyses of rs987237 in TFAP2B showed borderline
association with central obesity among women. The GWAS
showed no evidence of sex-specific associations. However,
TFAP2B was confirmed as an obesity locus in the recent meta-
analysis, where this variant associated with BMI at a genome-wide
significant level [23].
It is well known that substantial gender-specific differences in fat
distribution exist [18]. These have been shown to reflect genetic
influences i.e. on WC, and hip circumference, and for WHR the
genetic variance is almost twice as large in women than in men
[24]. The underlying molecular mechanisms are not clearly
understood. In this study, the observed effect sizes did not provide
sufficient statistical power to account for the gender stratification.
Therefore, we cannot exclude that the observed gender-specific
results reflect spurious findings. Further studies are needed to
investigate a putative influence of gender on the associations
observed for these variants.
Whether variation in the examined four genes is causal in
relation to obesity remain unclear. NRXN3 is expressed in the
brain, as many of the other recently discovered obesity loci, and
variants in NRXN3 may provide changes of the brain function
and behavior [11]. Eating disorders have been ascribed to the
hypothalamic part of the brain [25], and recently, NRXN3 has
been investigated in relation to addiction of alcohol and smoking
[11,12]. MSRA is thought to be involved in the oxidative damage
in cells but the molecular mechanisms are not yet elucidated.
Another candidate gene located near MSRA, the TRF1-
interacting ankyrin-related ADP-ribose polymerase (TNKS), has
been proposed as the causal gene for the association with central
obesity [8]. Previously, TFAP2B has been investigated for
associations with several phenotypes correlated to diabetes and
obesity [13,14,15,16,17], and has been proposed to be a new
gene for the metabolic syndrome. We showed an association
between central obesity and rs987237 TFAP2B minor G-allele,
however, we were not able to determine the underlying
phenotype for this association in the quantitative trait analysis
of obesity-related measures, nor did we show any association with
type 2 diabetes.
In conclusion, we found that several of the central obesity-
associated variants in LYPLAL1, NRXN3, MSRA, and TFAP2B
associated with metabolic and anthropometric traits among adult
Danes. However, analyses were made without adjusting for
multiple testing, and further studies are needed to elucidate the
involvement of LYPLAL1, NRXN3, MSRA, and TFAP2B in the
pathophysiology of obesity.
Materials and Methods
The studies were approved by the appropriate Regional Ethics
Committees, and were in accordance with the principles of the
Helsinki Declaration.
Study samples
This study comprises 15,326 Danish individuals ascertained
from four different study groups (Table S1): 1) the Inter99 cohort,
which is a population-based, randomized, non-pharmacological
intervention study of middle-aged individuals for the prevention of
ischemic heart disease (n=6,162 individuals, aged 30–61 years)
from the Research Centre for Prevention and Health in Glostrup,
Copenhagen (ClinicalTrials.gov ID-no.: NCT00289237) [26], 2) a
cohort comprising individuals with type 2 diabetes (n=1,695)
sampled at Steno Diabetes Center (SDC), 3) a randomized,
population-based group of unrelated middle-aged individuals
(n=730) examined at SDC, Copenhagen, and 4) The Danish
ADDITION screening cohort (n=6,739), which is part of the
Anglo-Danish-Dutch study of Intensive Treatment in People with
Screen-detected Diabetes in Primary Care (ClinicalTrials.gov ID-
no.: NCT00237548) [27].
A standandardized oral glucose tolerance test was undertaken in
volunteers of Inter99. In this cohort QT analyses were performed
in treatment-naive individuals involving individuals with normal
glucose tolerance, impaired fasting glucose and impaired glucose
tolerance. The exact numbers are given in tables. Patients with
known type 2 diabetes (n=124) were excluded from the QT
analyses.
To increase statistical power, QT analyses for BMI, WC, and
WHR were additionally performed including individuals from all
study populations with the respective phenotypes available. Again,
individuals with known type 2 diabetes were excluded. The
combined study sample comprised 13,507 individuals.
The case-control studies of type 2 diabetes included all
unrelated type 2 diabetic case patients and all glucose-tolerant
control individuals from study group 1–4. All control individuals
had normal fasting glycaemia and were glucose tolerant following
an oral glucose tolerance test. Individuals from study group 4
with BMI,25 kg/m
2 were excluded. Diabetes, impaired fasting
glucose, and impaired glucose tolerance were defined in accor-
dance with World Health Organization 1999 criteria [28].
In the case-control studies for overweight and obesity, central
obesity was estimated using WC and general obesity was estimated
using BMI. Overweight was defined as BMI$25 kg/m
2 and ,30
kg/m
2. Obesity was defined as BMI$30 kg/m
2. A lean control
individual was defined as BMI,25 kg/m
2. For WC the definition
of overweight and obesity was sex-specific. For women overweight
was defined as WC$80 cm and ,88 cm, and obesity as WC$88
cm. The definitions for men were a WC$94 cm and ,102 cm for
overweight, and a WC$102 cm for obesity. A lean control
individual was defined as WC,80 cm, for women, and WC,94
cm for men.
All participants were Danes by self-report. Before participation
informed written consent was obtained from all subjects.
Anthropometrical and biochemical measurements
The anthropometrical measurements of weight, height, WC,
and hip were performed in light indoor clothes without shoes. BMI
was calculated as weight in kg divided by height in m
2. WC was
measured midway between the iliac crest and the lower costal
Obesity-Related Variants and Metabolic Traits
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measured at the level of trochante major. WC and hip were
calculated in cm. The methods used to obtain biochemical
measurements have been described previously [26,27]. HOMA-
IR was calculated as: (fasting plasma glucose (mmol/l) 6 fasting
serum insulin (pmol/l))/22.5 [29].
Genotyping
The rs2605100 in LYPLAL1, rs10146997 in NRXN3, rs545854
(former rs7826222) in MSRA, and rs987237 in TFAP2B were
genotyped using KASParH with success rates .97% and error
rates = 0%. The risk-allele frequencies were 70% (rs2605100 G-
allele in LYPLAL1), 21% (rs10146997 G-allele in NRXN3), 15%
(rs545854 G-allele in MSRA), and 17% (rs987237 G-allele in
TFAP2B), which are in accordance with HapMap, and obeyed
Hardy-Weinberg equilibrium (p.0.05).
Statistical analyses
The four variants were investigated for associations with
quantitative metabolic traits. The quantitative variables were
tested for differences between genotyped groups using linear
regression, assuming an additive model. All analyses were
adjusted for sex, age, and BMI, when appropriate. BMI was
additionally adjusted for WC. P-values given in parentheses were
only adjusted for age and sex. Values of serum triglyceride, serum
insulin, HOMA-IR, and plasma glucose had non-normally
distributed residuals and were logarithmically transformed prior
to statistical analyses. Their effect sizes (b) are presented as an
increase/decrease in percent with 95% CI. Values without
transformation (BMI, WC, and WHR) are given as actual values
with 95% CI. The case-control studies were analyzed using
logistic regression, assuming an additive model. Here we included
type 2 diabetes patients, why these analyses were adjusted for sex,
age and diabetes treatment, and with or without BMI or WC,
respectively. Heterogeneity was assessed with the generic inverse
variance meta-analysis method (R package: meta), which
describes the proportion of variation in the effects that is
attributable to genuine differences across the study groups rather
than to random error.
To investigate whether the effect of the alleles differed between
genders, we included an interaction term between sex and the
genotype of interest in the linear model. In this model, we assumed
an additive effect for the genotypes and sex as a binary vector. All
statistical analyses were performed using R version 2.9.2. P-values
were not adjusted for multiple hypothesis testing and p,0.05 was
considered nominally significant.
Statistical power calculations in the case-control analyses were
done using CaTS, power calculations for large genetic association
studies, available at http://www.sph.umich.edu/csg/abecasis/
cats/. Depending on the type of analysis, as well as the risk allele
frequency (RAF) of the analyzed variant, we had between 72%
and 100% power to detect genetic effects in this study (p,0.05)
(Table S2). The lowest and the highest RAF of the examined SNPs
were 15% and 70%, respectively. Using the population-based
Inter99 cohort as reference, the prevalence of central overweight
and obesity in the Danish population were estimated to 23% and
22%, respectively, the prevalence of general overweight and
obesity in the Danish population were estimated to 39% and 17%,
respectively, and the prevalence of type 2 diabetes in the examined
Danish population was 5%. Our power calculations estimated a
statistical power of 99% and 100% to detect associations with
central overweight and obesity, respectively, for a variant with a
RAF of 15% with a relative risk of 1.15 (Table S2). The statistical
power estimates for quantitative traits were estimated in R using
1,000 simulations, n=6,162, and with a significance threshold of
0.05 (Table S2).
Supporting Information
Table S1 Characteristics for individuals included in the
analyses stratified according to study group. Data are
means 6 standard deviation. SDC, Steno diabetes center. WC,
waist circumference.
(DOCX)
Table S2 Quantitative metabolic traits in 5,769 treat-
ment-naı ¨ve middle-aged Danes from the population-
based Inter99 cohort according to LYPLAL1 rs2605100
genotype. Data are unadjusted means 6 standard deviation or
medians (interquartile range). Values of fasting serum triglycerides,
serum insulin, plasma glucose, and HOMA-IR were logarithmi-
cally transformed prior to statistical analyses, and their effect sizes
(b) are presented as the increase/decrease in percent. P-values
were calculated assuming an additive model (padd). Interaction
analysis (pint) was performed to test whether the effect of the alleles
differed between men and women. All analyses were adjusted for
age, sex, and BMI. Furthermore, waist circumference and waist-
hip ratio were adjusted for age and sex, and the p-values are shown
in parentheses.
(DOCX)
Table S3 LYPLAL1 rs2605100, NRXN3 rs10146997,
MSRA rs545854, and TFAP2B rs987237 in relation to
central obesity. Data are number of individuals, divided into
genotype groups. The effect is either the odds ratio (OR) or the per
allele effect size presented as the increase/decrease and 95%CI.
Effect and p-values shown are for an additive genetic model (padd)
and are adjusted for age, sex and diabetes treatment (without/
with BMI) for the obese cases, and QT analyses are adjusted for
age and sex (without/with BMI). QT, quantitative trait; WC, waist
circumference; WHR, waist-hip ratio.
(DOCX)
Table S4 LYPLAL1 rs2605100, NRXN3 rs10146997,
MSRA rs545854, and TFAP2B rs987237 in relation to
general obesity. Data are number of individuals, divided into
genotype groups. The effect is either the odds ratio (OR) or the
per allele effect size presented as the increase/decrease and
95%CI. Effect and p-values shown are for an additive genetic
model (padd) and are adjusted for age, sex and diabetes treatment
(without/ with WC) for the obese cases, and QT analyses are
adjusted for age and sex (without/with WC). QT, quantitative
trait.
(DOCX)
Table S5 Quantitative metabolic traits in 5,789 treat-
ment-naı ¨ve middle-aged Danes from the population-
based Inter99 cohort according to NRXN3 rs10146997
genotype. Data are unadjusted means 6 standard deviation or
medians (interquartile range). Values of fasting serum triglycerides,
serum insulin, plasma glucose, and HOMA-IR were logarithmi-
cally transformed prior to statistical analyses, and their effect sizes
(b) are presented as the increase/decrease in percent. P-values
were calculated assuming an additive model (padd). Interaction
analysis (pint) was performed to test whether the effect of the alleles
differed between men and women. All analyses were adjusted for
age, sex, and BMI. Furthermore, waist circumference and waist-
hip ratio were adjusted for age and sex, and the p-values are shown
in parentheses.
(DOCX)
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ment-naı ¨ve middle-aged Danes from the population-
based Inter99 cohort according to MSRA rs545854
genotype. Data are unadjusted means 6 standard deviation or
medians (interquartile range). Values of fasting serum triglycerides,
serum insulin, plasma glucose, and HOMA-IR were logarithmi-
cally transformed prior to statistical analyses, and their effect sizes
(b) are presented as the increase/decrease in percent. P-values
were calculated assuming an additive model (padd). Interaction
analysis (pint) was performed to test whether the effect of the alleles
differed between men and women. All analyses were adjusted for
age, sex, and BMI. Furthermore, waist circumference and waist-
hip ratio were adjusted for age and sex, and the p-values are shown
in parentheses.
(DOCX)
Table S7 Quantitative metabolic traits in 5,764 treat-
ment-naı ¨ve middle-aged Danes from the population-
based Inter99 cohort according to TFAP2B rs987237
genotype. Data are unadjusted means 6 standard deviation or
medians (interquartile range). Values of fasting serum triglycerides,
serum insulin, plasma glucose, and HOMA-IR were logarithmi-
cally transformed prior to statistical analyses, and their effect sizes
(b) are presented as the increase/decrease in percent. P-values
were calculated assuming an additive model (padd). Interaction
analysis (pint) was performed to test whether the effect of the alleles
differed between men and women. All analyses were adjusted for
age, sex, and BMI. Furthermore, waist circumference and waist-
hip ratio were adjusted for age and sex, and the p-values are shown
in parentheses.
(DOCX)
Table S8 Statistical power estimates. Central overweight:
,4,500 controls and ,3,700 overweight individuals. Preva-
lence=0.23 (Men with waist circumference $94 cm and ,102
cm and women with waist circumference $80 cm and ,88 cm
from the Inter99). General overweight: ,3,200 controls and ,7,000
overweight individuals. Prevalence=0.39 (Individuals with
BMI$25 kg/m
2 and BMI,30 kg/m
2 from the Inter99). Central
obesity: ,4,500 controls and ,7,000 obese individuals. Preva-
lence=0.22 (men with waist circumference $102 cm and women
with waist circumference $88cm from the Inter99). General obesity:
,3,200 controls and ,4,800 obese individuals. Prevalence=0.17
(Individuals with BMI$30 kg/m
2 from the Inter99). Type 2
diabetes: , 4,900 controls and , 3,500 type 2 diabetics. Preva-
lence=0.05 (Individuals with screen detected or known type 2
diabetes from the Inter99). The statistical power calculations for
quantitative traits were estimated in R using 1,000 simulations and
a significance threshold of 0.05. The statistical power calculations
in the case-control analyses were done using CaTS, power
calculations for large genetic association studies, available at
http://www.sph.umich.edu/csg/abecasis/cats/. RAF = risk al-
lele frequency.
(DOCX)
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